Comanagement With Nephrologist Care Is Associated With Fewer Cardiovascular Events Among Liver Transplant Recipients With Chronic Kidney Disease

Patrick T. Campbell, MD,1 Megan Kosirog, MD,1 Blessing Aghaulor, MD,1 Dyanna Gregory, MS,1 Stewart Pine, MD,1 Amna Daud, MBBS, MPH,2 Arighno Das, MD,1 Daniel J. Finn, MPH,1 Josh Levitsky, MD,1,2 Jane L. Holl, MD, MPH,3,4 Donald M. Lloyd-Jones, MD, ScM,5,6 and Lisa B. VanWagner, MD1,2,5

INTRODUCTION

Chronic kidney disease (CKD) is a common complication after liver transplant (LT), with an incidence of stage 4 or 5 CKD (defined as estimated glomerular filtration rate [eGFR], <30 mL/min per 1.73 m2) up to 18% at 5 y after LT.1 Many factors have been associated with increased risk of CKD post-LT, including pretransplant renal dysfunction, diabetes, hypertension, and immunosuppression with calcineurin inhibitors.1,2

Received 31 March 2021. Revision received 6 July 2021. Accepted 15 July 2021.

1 Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University, Chicago, IL.
2 Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
3 Center for Healthcare Delivery Science and Innovation, University of Chicago Medicine, Chicago, IL.
4 Biological Sciences Division, Department of Neurology, University of Chicago, Chicago, IL.
5 Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
6 Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.

This work was supported by a grant from the National Institutes of Health/National Heart, Lung, and Blood Institute to L.B.V. (K23HL136891). The Northwestern Medicine Enterprise Data Warehouse is funded, in part, by the National Center for Advancing Translational Sciences of the National Institute of Health research grant UL1TR001422 to the Northwestern University Clinical and Translational Sciences Institute.

Received 31 March 2021. Revision received 6 July 2021. Accepted 15 July 2021.

L.B.V. receives investigator-initiated grant support from W.L. Gore & Associates outside the scope of this work. The other authors declare no conflicts of interest. P.T.C. drafted the article and participated in data interpretation and performance of the research. M.K., B.A., A.Das, and D.J.F. participated in performance of the research. D.G. participated in data analysis. S.P. participated in performance of the research. A.Daud and J.L.H. participated in research design. J.L.H. and D.M.L.-J. participated in research design and writing of the article. L.B.V. participated in research design, writing of the article, data analysis, and data interpretation.

Supplemental digital content (SDC) is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal’s Web site (www.transplantationdirect.com).

Correspondence: Lisa B. VanWagner, MD, MSc, Department of Medicine, Division of Gastroenterology and Hepatology, 676 N Saint Clair St, Suite 1400, Chicago, IL 60611. (lwv@northwestern.edu).

Copyright © 2021 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ISSN: 2373-8731
DOI: 10.1097/TXD.0000000000001220

(Transplantation Direct 2021;7: e766; doi: 10.1097/TXD.0000000000001220. Published online 20 September, 2021.)
CKD is a well-known risk factor for cardiovascular (CV) disease in the general population. Among LT recipients (LTRs), CV disease is a leading cause of mortality, and renal dysfunction at the time of and immediately posttransplant is associated with higher risk of major CV events. In addition, other factors that have been associated with increased mortality after LT include pre-LT CKD, post-LT acute renal failure, and post-LT CKD.

Given the significant CKD burden in this patient population and the known negative effects of this condition on clinical outcomes, improvement in the management of CKD could have significant potential to improve clinical outcomes for LTRs.

In the general CKD population, prior data have shown that early nephrology referral for management of CKD is associated with lower hospitalizations and mortality rates. Consequently, current clinical practice guidelines for the general CKD population recommend nephrology referral for several clinical scenarios. These guidelines also provide recommendations on management of both CKD and many other chronic conditions that frequently occur in patients with CKD including hypertension, hyperlipidemia, diabetes, anemia, etc. Although the aforementioned clinical practice guidelines help guide management of patients with CKD, published guidance on the management of CKD among LTRs has focused on adapting key aspects from the nontransplant CKD guidelines that are most relevant to the transplant population, such as adjustment of immunosuppressive regimens to limit progression of CKD and therapeutic considerations to minimize drug–drug interactions for management of highly prevalent comorbid conditions (eg, diabetes, hypertension, proteinuria) in transplant recipients.

Despite the breadth of recommendations for CKD management and high prevalence of CKD in LTRs, data on transplant provider management of CKD among LTRs are limited. Therefore, this study sought to assess rates of nephrology comanagement for CKD and utilization of guideline-recommended medical therapy among LTRs with CKD and whether these metrics are associated with a reduction in CV events.

**MATERIALS AND METHODS**

**Study Design**

A longitudinal inception cohort study was conducted at a large, urban, tertiary care network in the United States. The institutional review board of Northwestern University approved the study.

**Study Population**

Patients who underwent LT between January 1, 2010, and December 31, 2016, were included in the study. We excluded patients who died within the first 6 mo after LT in an attempt to study patients with stable immunosuppression and graft function.

**Data Source and Collection**

Eligible LTRs were identified using International Classification of Diseases 9th or 10th Revision (ICD-9/10) codes and clinical information was obtained from the Northwestern Medicine Enterprise Data Warehouse, which contains comprehensive demographic, clinical, diagnostic, procedural, and administrative data for 7.5 million unique patients from all Northwestern Medicine sites. In addition, manual chart review was used for data that are not easily captured in an electronic health record (EHR), such as clinical reasoning for not adhering to a guideline recommendation (eg, documentation of why it would be inappropriate given the unique clinical scenario). Vital status was obtained from the Organ Procurement and Transplantation Network database, which is linked to the US Social Security Death Index. Data were linked to clinical data of each LTR based on a previously published methodology.

**CKD and Covariate Definitions**

Renal function was assessed by serum creatinine and corresponding eGFR calculated by the Modification of Diet in Renal Disease 4-variable equation. CKD was identified by ICD-9/10 code or by using eGFR on at least 2 separate outpatient visits separated by ≥90 d. CKD was defined as eGFR <60 mL/min/1.73 m². CKD plus those at risk was defined as eGFR <90 mL/min/1.73 m². At risk for CKD was defined as eGFR 60–89 mL/min/1.73 m². Renal replacement therapy pre- and post-LT was defined as at least 2 encounters for intermittent hemodialysis or continuous renal replacement therapy before or after LT. Patients undergoing renal replacement were assigned an eGFR of 0 mL/min/1.73 m², given the serum creatinine did not reflect actual renal function. Hypertension was identified by ICD-9/10 code, order of blood pressure (BP)-lowering medication, or systolic BP ≥140 or diastolic BP ≥90 mm Hg on at least 2 separate outpatient visits, consistent with clinical practice guidelines during the study period. Diabetes was identified by ICD-9/10 code, hemoglobin A1C ≥6.5%, random blood glucose ≥200 mg/dL, or use of glucose-lowering medication, in the setting of prednisone daily dose ≤10 mg. Atherosclerotic cardiovascular disease (ASCVD) was identified by ICD-9/10 code for acute coronary syndrome, myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, or transient ischemic attack. Obesity was defined as body mass index ≥30 kg/m² or ICD-9/10 code. Hyperlipidemia was identified by ICD-9/10 code, treatment with lipid-lowering medications, or total cholesterol ≥200 mg/dL. The standard model for end-stage liver disease (MELD) score was used because this was the allocation system in use during the study period. The immunosuppression and clinical visit protocol at our institution has been described previously.

**Assessment of CKD Management**

We used manual chart review to assess rates of nephrology comanagement among LTRs. Nephrology comanagement of CKD was defined as any referral to a nephrology specialist placed by a transplant provider during the study period or if a patient was already under the care of a nephrologist during the study period. We also assessed guideline-recommended medication use and average annual BP, using both manual and electronic chart review as described previously.

**Exposure and Outcome Measures**

The primary exposure variable was comanagement of CKD plus at-risk CKD by a nephrology specialist. The primary outcome variable was a CV event, defined as death from a CV cause or hospitalization for myocardial infarction/revascularization, cardiac arrest, heart failure, atrial fibrillation, thromboembolism, or stroke. In secondary analysis, we examined differences in rates of comanagement, process measures for CVD care, and associations with CV events among the
subgroups with CKD (eGFR, <60) and those at risk for CKD (eGFR, 60–89).

Statistical Analysis
A t test, chi-square test, or Fisher exact test was used to examine group differences by nephrology comanagement status for continuous or categorical variables, as appropriate. Study participants without a serum creatinine recorded post-LT were excluded from this analysis (n = 30). Cox proportional hazard models were used to estimate major CV events from time of LT between LTRs with CKD who were comanaged by a nephrologist and those who were not. Time of LT was taken as time zero as the majority of CKD diagnoses occurred within the first year of LT and a substantial proportion (20%) of patients were already under the care of a nephrologist at the time of LT. The proportional hazard assumption was met and residuals were normally distributed. The model was adjusted a priori for sex, race, age at transplant and time-varying diabetes, ASCVD, use of BP-lowering medication, and CKD stage. SAS software version 9.4 (SAS Institute, Cary, NC) was used to complete all analyses. All P values are 2-sided and a P<0.05 was considered to indicate statistical significance.

RESULTS

Demographics
Among the 602 patients transplanted during the study period that survived at least 6 mo and had a minimum of 1-y follow-up time, 79.1% (n = 476) met criteria for diagnosis of CKD (eGFR, <60 mL/min/1.73 m²) or at risk for CKD (eGFR, 60–89 mL/min/1.73 m²) during the study time period. Out of these 476 patients, 416 met criteria for CKD (eGFR, <60 mL/min/1.73 m²) and 60 met criteria for at risk for CKD (eGFR, 60–89 mL/min/1.73 m²). The prevalence of CKD plus those at risk (eGFR, <90 mL/min/1.73 m²) at time of LT was 41.5% and increased yearly post-LT from 71% in year 1 to 86% in year 6 (P<0.0001). The prevalence of CKD (eGFR, < 60 mL/min/1.73 m²) also increased yearly post-LT from 41% in year 1 to 66% in year 6 (P<0.0001) (Figure 1).

Cohort characteristics of LTRs with CKD or at risk for CKD stratified by nephrology comanagement status are shown in Table 1. The average age at time of LT was 57±11 y, 60.7% of LTRs were men, 64.1% of LTRs identified as non-Hispanic White, and 17.9% were of Hispanic ethnicity. The most common indication for LT was hepatitis C (32.4%), followed by alcohol (22.1%), autoimmune (13.1%), and non-alcoholic steatohepatitis (12.9%). The mean MELD score at transplant was 24. LTRs with CKD or at risk for CKD who were comanaged with nephrology had higher rates of comorbid diabetes (43% versus 30%, P=0.006) and higher mean MELD at time of LT (27.1 versus 21.7, P<0.0001) compared with those that were not. There was no difference in prevalence of hypertension (59% with nephrology comanagement versus 53% without, P=0.16), mean systolic BP level (133.9 mmHg with comanagement versus 131.9 mmHg without, P=0.051), or BP medication usage (59% with comanagement versus 61% without, P=0.78) by nephrology comanagement status.

Process of Care Measures
The rates of nephrology comanagement among those with any stage or at risk for CKD decreased yearly post-LT from 35% in year 1 to 28% in year 6. Rates of nephrology comanagement among those with CKD ranged from 30% to 42% annually post-LT. Table 2 demonstrates adherence to clinical practice guidelines yearly after transplant among LTRs who were comanaged with nephrology and those who were not. Among all LTRs with or at risk for CKD, only 5%–10% had a serum creatinine and a urine albumin:creatinine ratio obtained annually as recommended by clinical practice guidelines.19 Less than 5% of LTRs with or at risk for CKD were offered a low-salt diet at least once yearly. Angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker

![FIGURE 1. Prevalence of CKD plus those at risk (eGFR, <90 mL/min/1.73 m²), CKD (eGFR, <60 mL/min/1.73 m²), and those at risk for CKD (eGFR, 60–89 mL/min/1.73 m²) by year from liver transplant. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; LTR, liver transplant recipient.](image-url)
(ARB) therapy was offered to 8%–24% of LTRs with CKD and 9%–33% in those at risk for CKD. Among LTRs with or at risk for CKD and diabetes, ACEi/ARB therapy was offered to 11%–39% annually. However, in stratified analysis, LTRs who were comanaged by a nephrologist and who were at risk or had CKD and had diabetes were offered ACEi or ARB therapy at a higher frequency than those that were not comanaged by a nephrologist (12%–53% versus 9%–29% annually, respectively). There was a statistically significant difference between these annual adherence rates for 3 of the 6 post-LT y (year 2 \(P = 0.03\), year 4 \(P = 0.01\), year 6 \(P = 0.03\)). Among LTRs with or at risk for CKD was defined by ICD-9/10 diagnosis codes or estimated glomerular filtration rate <90 mL/min/1.73 m\(^2\) on at least 2 occasions separated by at least 90 d.

CV Events

During a median follow-up of 3.5 y from transplant, 14.3% of LTRs experienced a CV event. The incidence rate for CV events among LTRs with or at risk for CKD was 40.1 events per 1000 person-y of follow-up time. The unadjusted CV event incidence rate was higher among LTRs with CKD (n=66, 47.7 events per 1000 person-y of follow-up time) compared with those at risk for CKD (n=11, 20.5 events per 1000 person-y of follow-up time). In unadjusted analyses, comanagement by a nephrologist among LTRs with or at risk for CKD was not statistically associated with major CV events (hazard ratio, 0.67; 95% confidence interval [CI], 0.38–1.17). However, when the model was adjusted for potential confounders including age at LT, sex, race and time-varying diabetes, ASCVD, and CKD stage, nephrology comanagement was associated with a 42% lower incidence of major CV events (adjusted hazard ratio [aHR], 0.58; 95% CI, 0.42–0.82). When additionally adjusted for time-varying use of BP-lowering medications, the association was attenuated but remained significant (aHR, 0.57; 95% CI, 0.33–0.99). When the analysis was restricted to only LTRs with CKD (eGFR, <60) or only those at risk (eGFR, 60–89), nephrologist comanagement was not associated with lower major CV events (aHR, 1.05; 95% CI, 0.66–1.68 and aHR, 0.60; 95% CI, 0.27–1.34, respectively). In secondary analysis, offering of ACEi or ARB therapy among LTRs with or at risk for CKD was not associated with lower overall mortality (aHR, 1.34; 95% CI, 0.89–2.01) or major CV events (aHR, 1.31; 95% CI, 0.92–1.86). Similar findings were found among LTRs with CKD (aHR, 1.14; 95% CI, 0.69–1.90 for overall mortality and aHR, 1.03; 95% CI, 0.69–1.53 for major CV events).

### TABLE 1.

| Cohort characteristics of LT recipients with or at risk for CKD (n = 476) by nephrology comanagement status at time of liver transplant |
|---------------------------------------------------------------|
| **With or at risk for CKD** (n = 476) | **Nephrology comanagement** (n = 202) | **No nephrology comanagement** (n = 274) | **P** |
| Age at LT, mean (SD), y | 57 (11) | 58 (10) | 57 (11) | 0.27 |
| Men | 60.7 | 62.4 | 59.5 | 0.52 |
| Race/ethnicity | | | | 0.49 |
| White | 64.1 | 61.6 | 66.1 | |
| Black | 9.5 | 10.5 | 8.8 | |
| Hispanic | 17.9 | 20.5 | 16.0 | |
| Other | 8.4 | 7.4 | 9.1 | |
| BMI, mean (SD), kg/m\(^2\) | 29.8 (6.9) | 29.9 (7.1) | 29.8 (6.7) | 0.81 |
| Hypertension | 55.7 | 59.4 | 52.9 | 0.16 |
| BP medication use | 60.0 | 58.9 | 60.6 | 0.783 |
| Hyperlipidemia | 26.5 | 27.7 | 25.6 | 0.59 |
| Diabetes | 35.5 | 42.6 | 30.3 | 0.006\(^a\) |
| ASCVD | 46.8 | 51.0 | 43.8 | 0.12 |
| UNOS MELD at LT, mean (SD) | 24.0 (10.5) | 27.1 (10.3) | 21.7 (10.0) | <0.0001\(^a\) |
| LT indication | | | | 0.41 |
| HCV | 32.4 | 31.3 | 33.3 | |
| Alcohol | 22.1 | 22.9 | 21.6 | |
| NASH | 12.9 | 15.4 | 11.0 | |
| HBV | 4.7 | 5.0 | 4.4 | |
| Autoimmune | 13.1 | 9.4 | 15.8 | |
| Cryptogenic | 7.4 | 7.5 | 7.3 | |
| Other | 7.4 | 8.5 | 6.6 | |

Data expressed as % unless otherwise noted.

Hypertension defined by the ICD-9/10 diagnosis codes, use of BP-lowering medication, systolic blood pressure ≥140 mm Hg, or diastolic BP ≥90 mm Hg on at least 2 separate visit dates.

Hyperlipidemia defined by ICD-9/10 codes, total cholesterol ≥200 mg/dL, or use of lipid-lowering medication.

Diabetes defined by ICD-9/10 codes, A1c ≥6.5%, or use of glucose-lowering medication.

ASCVD defined by ICD-9/10 code for acute coronary syndrome, myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, or transient ischemic attack.

With or at risk for CKD was defined by ICD-9/10 diagnosis codes or estimated glomerular filtration rate <90 mL/min/1.73 m\(^2\) on at least 2 occasions separated by at least 90 d.

\(^a\)Value <0.05, \(\chi^2\) test or pooled \(t\) test used where appropriate.

ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; HBV, hepatitis B virus; HCV, hepatitis C virus; ICD-9/10, International Classification of Diseases, 9th and 10th Revisions; LT, liver transplant; MELD, model for end-stage liver disease; NASH, nonalcoholic steatohepatitis; UNOS, United Network for Organ Sharing.


**TABLE 2.** Adherence to clinical practice guidelines yearly after transplant among liver transplant recipients who were comanaged by nephrology compared with those who were not

| Y post liver transplant | 1 | 2 | 3 | 4 | 5 | 6 |
|-------------------------|---|---|---|---|---|---|
| Serum Cr + Ur microalbumin:Cr ratio | + Comanagement | 13/150 (8.7%) | 19/141 (13.5%) | 16/121 (13.2%) | 7/84 (8.3%) | 7/61 (11.5%) | 9/38 (23.7%) |
| − Comanagement | 46/294 (15.6%) | 28/271 (10.3%) | 16/198 (8.1%) | 6/150 (4.0%) | 4/101 (4.0%) | 0/48 (0%) |
| \( P \) | 0.04 | 0.34 | 0.05 | 0.06 | 0.001 | 0.001 |
| With or at risk for CKD, offered low-salt diet | + Comanagement | 5/150 (3.3%) | 5/141 (3.5%) | 2/121 (1.7%) | 1/84 (1.2%) | 0/61 (0%) |
| − Comanagement | 15/275 (5.5%) | 11/262 (4.2%) | 3/223 (1.3%) | 1/148 (0.7%) | 0/101 (0%) |
| \( P \) | 0.32 | 0.74 | 0.63 | 0.26 | 0.40 | 0.40 |
| With or at risk for CKD and HTN, BP <130/80 mm Hg | + Comanagement | 4/143 (2.8%) | 7/132 (5.3%) | 9/115 (7.8%) | 9/79 (11.4%) | 3/60 (5.0%) |
| − Comanagement | 9/253 (3.6%) | 16/242 (6.6%) | 19/202 (9.4%) | 18/177 (10.2%) | 14/142 (9.9%) |
| \( P \) | 0.78 | 0.61 | 0.63 | 0.77 | 0.26 | 0.40 |
| At risk for CKD (eGFR, 60–89), offered ACEi/ARB | + Comanagement | 1/7 (1.4%) | 1/6 (16.7%) | 0/4 | 1/3 (33.3%) | 2/5 (40.0%) |
| − Comanagement | 3/36 (8.3%) | 2/38 (5.3%) | 0/39 | 2/34 (5.9%) | 2/22 (9.1%) |
| \( P \) | 0.52 | 0.36 | 0.23 | 0.13 | 0.11 |
| CKD (eGFR, <60), offered ACEi/ARB | + Comanagement | 29/130 (22.3%) | 32/129 (25.4%) | 9/114 (7.9%) | 23/79 (29.1%) | 15/55 (27.3%) |
| − Comanagement | 47/172 (27.3%) | 39/180 (21.7%) | 13/155 (8.4%) | 27/141 (19.1%) | 26/111 (23.4%) |
| \( P \) | 0.32 | 0.52 | 0.88 | 0.09 | 0.59 |
| With or at risk for CKD and DM, offered ACEi/ARB | + Comanagement | 28/84 (33.3%) | 29/86 (33.7%) | 9/74 (12.2%) | 22/51 (43.1%) | 16/40 (40.0%) |
| − Comanagement | 39/141 (27.7%) | 28/135 (20.7%) | 10/107 (9.3%) | 19/89 (21.3%) | 21/72 (29.2%) |
| \( P \) | 0.37 | 0.35 | 0.54 | 0.01 | 0.24 |

With or at risk for CKD defined as eGFR <90 mL/min/1.73 m² on at least 2 occasions separated by at least 90 d.

With or at risk for CKD defined as eGFR <60 mL/min/1.73 m² on at least 2 occasions separated by at least 90 d.

At risk for CKD defined as eGFR <60 mL/min/1.73 m² on at least 2 occasions separated by at least 90 d.

Hypertension defined by ICD-9/10 diagnosis codes or use of BP-lowering medication or systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg on at least 2 separate visit dates.

Diabetes defined by ICD-9/10 codes or A1c ≥6.5% or use of glucose-lowering medication.

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure; CKD, chronic kidney disease; Cr, creatinine; DM, diabetes; eGFR, estimated glomerular filtration rate; HTN, hypertension; ICD-9/10, International Classification of Diseases, 9th and 10th Revisions; Ur, urinary; + comanagement, nephrology referral placed and not already established with nephrologist; − comanagement, nephrology referral not placed and not already established with nephrologist.

**DISCUSSION**

We observed a significant association between nephrology comanagement of persons with or at risk for CKD and fewer major CV events among LTRs. However, rates of nephrology referral in this population were low. In addition, rates of adherence to guideline-directed quality measures associated with CV risk reduction were almost uniformly low. These findings suggest the hypothesis that transplant provider practices need to be critically evaluated and redesigned to help facilitate comanagement of LTRs with CKD with nephrologists, which could improve adherence to CKD clinical practice guidelines and subsequent outcomes.

Current clinical practice guidelines for the general CKD population recommend nephrology referral for several indications including GFR <30 mL/min/1.73 m², albuminuria, acute kidney injury, or progression of CKD. ACEi or ARB therapy is recommended for patients with CKD and evidence of proteinuria (albumin excretion, >300 mg/24 h) or diabetic nephropathy, which has been shown to improve proteinuria and delay CKD progression. Although studies on ACEi/ARB therapy have failed to show a reduction in major CV events when used for CKD, these classes of medications have been shown to improve outcomes when used for several cardiac indications including post-myocardial infarction and heart failure with reduced ejection fraction. Although these guidelines, only 8.7% of patients with stage 3, 39% with stage 4, and 32% with stage 5 CKD were seeing a nephrology specialist for comanagement of CKD in the Veterans Affairs Health System. This is similar to the rates we found for nephrology comanagement of CKD among LTRs, with overall low rates of nephrology comanagement that are slightly higher for those with true CKD compared with those with CKD plus those at increased risk (30%–42% versus 28%–35%). Recent work by our group identified several barriers to providing multidisciplinary CV disease prevention care to LTRs, including (1) lack of awareness of CV disease risk after LT, (2) lack of confidence in an ability to provide proper CV disease care to LTRs, (3) reluctance to provide CVD care without transplant provider review, and (4) complexity of communication with the multidisciplinary LTRs care team about CVD care. These identified barriers provide potential targets for quality improvement initiatives to improve comanagement of prevalent CV disease risk factors, such as CKD, among LTRs.

Although comanagement of CKD and its association with clinical outcomes has not previously been studied in LTRs, it has been associated with better outcomes in the general CKD population. A systematic review of 27 longitudinal cohort studies found that early nephrology referral for management of CKD was associated with lower hospitalization and mortality rates. The results of the present study extend these findings into the LT population and show that nephrology comanagement was borderline significantly associated with a reduction in CV events, after adjusting for age, sex, race,
ASCVD, and CKD stage in the CKD population. However, when the target population was expanded to include those at risk for CKD (eGFR threshold, <90), nephrology comanagement was associated with a 43% reduction in CV events independent of important confounders. If the observed association is causal, it is unclear at present how nephrology comanagement was responsible for a reduction in CV events. It could be hypothesized that LTRs comanaged by nephrology specialists might have higher rates of adherence to key clinical practice guidelines that have been demonstrated to improve clinical outcomes (eg, ACEi/ARB therapy, BP control <130/80 mm Hg). However, when further adjusting the multivariable models by use of BP-lowering medications or when stratifying adherence to clinical practice guidelines by nephrology comanagement status, we did not see any difference in rates of target BP achieved. We also did not see a significant difference in rates of ACEi/ARB therapy in those at risk for CKD compared with those with CKD. However, among LTRs with both CKD and diabetes, we did see a statistically significant difference in rates of ACEi/ARB therapy by nephrology comanagement status in 3 of the 6 posttransplant years, which could possibly explain some of the association between nephrology comanagement and CV outcomes because ACEi/ARB therapy has been shown to improve both renal and CV outcomes in the nontransplant population. In an attempt to further evaluate this possibility, we assessed mortality and CV outcomes by ACEi/ARB therapy, but there was not an association between offering of ACEi/ARB therapy and overall mortality or major CV events. However, the overall low rates of ACEi/ARB therapy being offered in this population limit our power to detect any associations. Although rates of CKD in the LT population are high and increase yearly post-LT, <10% of LTRs were screened with serum creatinine and urine microalbumin:creatinine ratio yearly. Additionally, adherence rates to other key elements of the general CKD guidelines were also poor. Less than 6% of LTRs with CKD had EHR documentation that a low-salt diet was offered annually and most (88%) LTRs with CKD and hypertension did not achieve the guideline-directed average yearly BP target of <130/80 mm Hg. These findings highlight key areas for improvement in both screening for CKD and guideline-directed management of CKD among LTRs.

This study has several limitations that warrant discussion. These findings are from a single tertiary care network, and as a result, the practice patterns described here may not be generalizable to all transplant centers. However, this is the first study to report on the association between comanagement of CKD among LTRs and CV events, which are a leading cause of death after LT. Future studies should include participants from multiple institutions with diverse sex and racial-ethnic backgrounds to help make these results more generalizable to the entire LT population. Another limitation of this study is its observational nature, which does not allow us to infer causality. There is also the possibility for residual confounding and confounding by indication/referral bias that is not captured with documentation in the EHR. Another limitation is that a significant proportion of LTRs were already under the care of a nephrologist at the time of LT, and many had care encounters outside of our hospital network. Thus, there is a potential for reverse causality as date of nephrology encounters is not available in all patients. In addition, a patient was considered referred to nephrology if the patient had a referral placed in the EHR, documentation that a referral was made to nephrology, or if they were documented as currently seeing a nephrologist. A limitation of this approach is that patients seeing a nephrologist outside of our academic medical network might not have had these encounters documented, and therefore might have inappropriately been classified as not being referred to nephrology. Future prospective studies capturing actual number of encounters with nephrology specialists will be useful to identify barriers to nephrology referral for LTRs with CKD and consider possible mechanisms that may lead to reduced CV events in this population.

In conclusion, although nephrology comanagement of CKD among LTRs with CKD or at risk for CKD was associated with improved CV outcomes, rates of nephrology comanagement among this population were low. In addition, adherence rates to clinical practice guidelines for management of CKD were poor. These findings have emphasized a unique area for improvement in the clinical care of this high-risk population and a need for further study. Large, multi-institution, prospective studies would be useful to understand the generalizability of these results and identify barriers to nephrology referral and guideline-recommended management of CKD among LTRs.

REFERENCES

1. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–940.
2. Corman SL, Foley RN, Schoniger KS. Effect of long-term tacrolimus immunosuppression on renal function in liver transplant recipients. Pharmacotherapy. 2006;26:1433–1437.
3. Gansevoort RT, Comerota RJ, Hämäläinen BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–352.
4. VanWagner LB, Lapin B, Levitsky J, et al. High early cardiovascular mortality after liver transplantation. Liver Transpl. 2014;20:1306–1316.
5. VanWagner LB, Serper M, Kang R, et al. Factors associated with major adverse cardiovascular events after liver transplantation among a national sample. Am J Transplant. 2016;16:2684–2694.
6. Sharma P, Welch K, Ekstedt R, et al. Racial outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl. 2009;15:1142–1148.
7. Zand MS, Orloff MS, Abt P, et al. High mortality in orthotopic liver transplant recipients who require hemodialysis. Clin Transplant. 2011;25:213–221.
8. Cullaro G, Verna EC, Lee BP, et al. Chronic kidney disease in liver transplant candidates: a rising burden impacting post-liver transplant outcomes. Liver Transpl. 2020;26:498–506.
9. Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. Am J Med. 2011;124:1073–1080.e2.
10. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
11. Levitsky J, O’Leary JG, Asrani S, et al. Protecting the kidney in liver transplant recipients: practice-based recommendations from the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant. 2016;16:2532–2544.
12. Salvalaggio PR, Dzebisashvili N, MacLeod KE, et al. The interaction among donor characteristics, severity of liver disease, and the cost of liver transplantation. Liver Transpl. 2011;17:233–242.
13. Levey AS, Coresh J, Greene T, et al; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Am J Kidney Dis. 2006;47:243–254.
14. Levey AS, Coresh J, Balk E, et al; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147.
15. Levey AS, Eckardt K-U, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–2100.
16. VanWagner LB, Holl JL, Montag S, et al. Blood pressure control according to clinical practice guidelines is associated with decreased mortality and cardiovascular events among liver transplant recipients. *Am J Transplant.* 2020;20:797–807.

17. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med.* 2001;345:861–869.

18. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. *Lancet.* 1999;354:359–364.

19. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med.* 2001;345:851–860.

20. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. *Circulation.* 1998;97:2202–2212.

21. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. *Lancet.* 2000;355:1575–1581.

22. Heran BS, Musini WM, Bassett K, et al. Angiotensin receptor blockers for heart failure. *Cochrane Database Syst Rev.* 2012;2012:CD003040.

23. Centers for Disease Control and Prevention. Chronic Kidney Disease Initiative. Available at http://www.cdc.gov/ckd. Accessed January 11, 2020.

24. VanWagner LB, Gordon E, Adamski L, et al. Liver transplant recipient, caregiver, and provider perceptions of cardiovascular disease and related risk factors after transplant. *Liver Transpl.* 2021;27:668–683.

25. Watt KDS, Pedersen RA, Kremers WK, et al. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. *Am J Transplant.* 2010;10:1420–1427.